BofA/Merrill Lynch Downgrades Pacira Pharmaceuticals (PCRX) to Underperform
Get Alerts PCRX Hot Sheet
Price: $29.29 --0%
Rating Summary:
16 Buy, 11 Hold, 1 Sell
Rating Trend: Up
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 36
Rating Summary:
16 Buy, 11 Hold, 1 Sell
Rating Trend: Up
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 36
Join SI Premium – FREE
BofA/Merrill Lynch downgraded Pacira Pharmaceuticals (NASDAQ: PCRX) from Neutral to Underperform with a price target of $110.00 (from $112.00).
Analyst Steve Byrne said high expectations are priced in, with more potential to miss than to exceed views.
The firm lowered FY 2015 EPS from $2.53 to $2.14 and FY 2016 EPS from $6.43 to $5.70.
For an analyst ratings summary and ratings history on Pacira Pharmaceuticals click here. For more ratings news on Pacira Pharmaceuticals click here.
Shares of Pacira Pharmaceuticals closed at $119.27 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jefferies Double Upgrades Hemnet Group AB (HEM:SS) to Buy
- JPMorgan Downgrades Intrum AB (INTRUM:SS) to Underweight 'Following the appointment of Houlihan Lokey and Milbank as advisors'
- Jefferies Starts Zoom Video (ZM) at Hold
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT Change, Downgrades, Hot DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!